EUCTR2010-023946-58-NL进行中（未招募）不适用
Immunogenicity and safety of an adjuvant hepatitis B vaccine (fendrix) compared to Engerix in non-responding HIV-infected patients
ErasmusMC0 个研究点开始时间: 2011年1月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligible patients must be on HAART, with HIV-RNA < 200 copies/ml and CD4+-cell counts > 200/ml and negative HBsAg, anti-HBc and anti-HBs titers.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria
- •-co-infection with hepatitis C
- •-pregnancy
- •-radiation therapy
- •-cytotoxic agents
- •-any immunemodulator
研究者
相似试验
已完成
2 期
Immunogenicity and safety of an adjuvant hepatitis B vaccine (fendrix) compared to Engerix in non-responding HIV-infected patientsefficacy and safety of 2 different hepatitis B vaccinations10047438NL-OMON36269Erasmus MC, Universitair Medisch Centrum Rotterdam50
已完成
不适用
Evaluation of Immunogenicity and Safety of Hepatitis A Vaccine in AdolescentsCertain infectious and parasitic diseasesKCT0000407Ewha Womans University Medical Center300
已完成
1 期
Heptavalent Conjugate Vaccine against Pneumococcal (VCN7-T) in healthy infants and children.Pneumococcal infectionRPCEC00000173Biomolecular Chemistry Center (CQB)
已完成
1 期
Heptavalent Conjugate Vaccine against Pneumococcal in healthy adults (VCN7-T).Pneumococcal infection.RPCEC00000133Biomolecular Chemistry Center (CQB)40
进行中（未招募）
1 期
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract.The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of divergent histologies (i.e. squamous-cell tumor, adenocarcinoma, small cell carcinoma, micropapillary variant) may be acceptable provided that there is an important prevalence (> 90%) of urothelial component.MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2020-001028-32-FRCHU DE NIMES99